New and investigational antiepileptic drugs.
In the last fifteen years, new antiepileptic medications have been offered for the treatment of patients with epilepsy. Nevertheless, despite optimal medical treatment, up to 30% of patients still experience recurrent seizures and the challenge for new, more efficacious and better-tolerated drugs continues. New antiepileptic drugs include the evolution of pre-existing drugs and new compounds identified through the investigation of additional molecular targets, such as SV2A synaptic vesicle protein, voltage-gated potassium channels, ionotropic and metabotropic glutamate receptors, and gap junctions. This paper reviews the available information on various classes of molecules that are in the pipeline as well as on the innovative approaches to the treatment of epilepsy.
Striano
Pasquale
P
Muscular & Neurodegenerative Diseases Unit, Institute G. Gaslini, Genova, Italy.
Striano
Salvatore
S
D000596:Amino Acids / Q000737:chemistry / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use*; D055423:Diet, Ketogenic; D016503:Drug Delivery Systems; D015507:Drugs, Investigational / Q000627:therapeutic use*; D004827:Epilepsy / Q000178:diet therapy / Q000188:drug therapy*; D006801:Humans; D018377:Neurotransmitter Agents / Q000627:therapeutic use; D013237:Stereoisomerism
D000596:Amino Acids; D000927:Anticonvulsants; D015507:Drugs, Investigational; D018377:Neurotransmitter Agents